AtriCure, Inc.

Equities

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
23.17 ^USD	+2.48%		-0.13%	-35.08%

Apr. 23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
Apr. 18	AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	CI

Atricure, Inc. Provides Earnings Guidance for 2024

February 15, 2024 at 04:01 pm EST

AtriCure, Inc. provided earnings guidance for 2024. For Full year 2024 revenue is projected to be approximately $459 million to $466 million, reflecting growth of approximately 15% to 17% over full year 2023.

Latest news about AtriCure, Inc.

Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	Apr. 23	MT
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	Apr. 18	CI
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	Mar. 07	MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	Feb. 27	CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	Feb. 16	MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	Feb. 16	MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	Feb. 16	MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	Feb. 15	MT
Transcript : AtriCure, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M	Feb. 15	MT
Atricure, Inc. Provides Earnings Guidance for 2024	Feb. 15	CI
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	Jan. 22	MT
Transcript : AtriCure, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	Jan. 10
AtriCure Reports Higher Preliminary Q4, 2023 Revenue; Issues 2024 Revenue Guidance; Shares Rise	Jan. 08	MT
AtriCure, Inc. and Its Wholly Owned Subsidiary, Atricure, LLC Enters into an Asset-Based Credit Agreement	Jan. 08	CI
Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024	Jan. 08	CI
AtriCure, Inc. Appoints Shlomi Nachman to its Board of Directors	Jan. 04	CI
AtriCure's Q3 Adjusted Loss Narrows, Revenue Rises; Full-Year Guidance Adjusted	Nov. 01	MT
Transcript : AtriCure, Inc., Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
Earnings Flash (ATRC) ATRICURE Posts Q3 Revenue $98.3M, vs. Street Est of $96.6M	Nov. 01	MT
AtriCure, Inc. Provides Revenue Guidance for the 2023	Nov. 01	CI
AtriCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	23-10-23	MT
UBS Initiates AtriCure With Buy Rating, Price Target is $56	23-09-29	MT

Chart AtriCure, Inc.

Duration

Period

More charts

Company Profile

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AtriCure, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.17 USD

Average target price

51.89 USD

Spread / Average Target

+123.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ATRICURE, INC.	-35.08%	1.12B
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution